A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).
NCT ID: NCT00383019
Last Updated: 2021-09-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
300 participants
INTERVENTIONAL
2006-11-14
2007-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension
NCT00219596
Efficacy and Tolerability of Xalatan in Patients
NCT00950690
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.
NCT00143208
Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.
NCT00140062
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
NCT00140049
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Xalatan
Xalatan
latanoprost 0.005%, one rop once daily in evening
Xalacom
Xalacom
latanoprost 0.005% adn timolol 0.5%, one drop, once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xalatan
latanoprost 0.005%, one rop once daily in evening
Xalacom
latanoprost 0.005% adn timolol 0.5%, one drop, once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* History of trabeculectomy
* History of other ocular surgery including ALT, SLT,and trabeculotomy within 6 months
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nomura Eye Clinic
Ichinomiya, Aichi-ken, Japan
Matsusura Eye Clinic
Ichinomiya, Aichi-ken, Japan
Yasuma Eye Clinic
Nagoya, Aichi-ken, Japan
TANABE Eye Clinic
Nagoya, Aichi-ken, Japan
Suzuki Eye Clinic
Nagoya, Aichi-ken, Japan
Mitsuhashi Eye Clinic
Narashino, Chiba, Japan
Ohtsuka Eye Clinic
Sapporo, Hokkaido, Japan
Sasamoto Eye Clinic
Sapporo, Hokkaido, Japan
Ohyachi Kyouritsu Eye Clinic
Sapporo, Hokkaido, Japan
Kaimeido Eye Clinic
Sapporo, Hokkaido, Japan
Kobe University Hospital
Koube, Hyōgo, Japan
Kanazawa university hospital
Kanazawa, Ishikawa-ken, Japan
Lumine Hatano Eye Clinic
Fujisawa, Kanagawa, Japan
Tanino clinic
Kamakura, Kanagawa, Japan
Aoki eye clinic
Sagamihara, Kanagawa, Japan
Kikuna Yuda Eye Clinic
Yokohama, Kanagawa, Japan
Fujita Eye Clinic
Sapporo, Kokkaido, Japan
Chihara Eye Clinic
Uji, Kyoto, Japan
Miyata Eye Hospital
Miyakonojō, Miyazaki, Japan
Hayashi Eye Clinic
Kumagaya, Saitama, Japan
Hiraoka Eye Clinic
Tokorozawa, Saitama, Japan
Hanasaki Eye Clinic
Fuji, Shizuoka, Japan
Nakajima Eye Clinic
Fuji, Shizuoka, Japan
Yoshimura Eye & Internal Medical Clinic
Mishima, Shizuoka, Japan
Muramatsu Ganka Clinic
Susono, Shizuoka, Japan
The University of Tokyo Hospital
Bunkyo-ku, Tokyo, Japan
Tokyo Metropolitan Police Hospital
Chiyoda City, Tokyo, Japan
Ochanomizu Inoue Eye Clinic
Chiyoda-ku, Tokyo, Japan
Keio Hachioji Matsumoto Eye Clinic
Hachiōji, Tokyo, Japan
Manabe Clinic
Hamura, Tokyo, Japan
Tokyo Sugita Eye Center
Katsushika-ku, Tokyo, Japan
Kiyosenomori Hospital
Kiyose, Tokyo, Japan
Miyazaki Eye Clinic
Koto-ku, Tokyo, Japan
Takase Ganka Tairamachi Clinic
Meguro City, Tokyo, Japan
Ohashi Eye Clinic
Meguro-ku, Tokyo, Japan
Kunitoshi Eye Clinic
Musashino, Tokyo, Japan
Shimizu Eye Clinic
Musashino, Tokyo, Japan
WAKABA Eye Clinic
Ōta-ku, Tokyo, Japan
Seijo Clinic
Setagaya City, Tokyo, Japan
Yotsuya Shirato Ganka
Shinjuku, Tokyo, Japan
Tachihi Bill clinic
Tachikawa, Tokyo, Japan
Ueno Eye Clinic
Taito-ku, Tokyo, Japan
Hayashi Eye Hospital
Fujuoka, , Japan
Hayashi Tennjin Eye Clinic
Fukuoka, , Japan
Ohshima Hospital of Opthalmology
Fukuoka, , Japan
Kato Eye Clinic
Fukuoka, , Japan
Gifu University Hospital
Gifu, , Japan
Hiroshima University Hospital
Hiroshima, , Japan
Niigata University Medical and Dental Hospital
Niigata, , Japan
Nishi Eye Hospital
Osaka, , Japan
Adachi Eye Clinic
Osaka, , Japan
Osaka Welfare Pension Hospital
Osaka, , Japan
Nanba Opthalmology
Shizuoka, , Japan
Sugita Eye Hospital
Sugita, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6641050
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.